Clinical Efficacy And Safety Of The Shugan Jieyn Capsule Combined With Pinaverium Bromide For Diarrhea-type Irritable Bowel Syndrome

BackgroundShugan Jieyu Capsule,as a traditional Chinese medicine(TCM),is widely used in functional dyspepsia(FD)and has achieved good clinical results.There is no relevant study for the treatment of Irritable bowel syndrome(IBS),which is also a functional bowel disease.ObjectiveTo explore clinical efficacy and safety of the Shugan Jieyu capsule combined with pinaverium bromide for diarrhea-type irritable bowel syndrome(IBS-D).MethodsA total of 190 patients with diarrhea-type irritable bowel syndrome diagnosed in the Department of Gastroenterology,Qilu Hospital of Shandong University from June 2017 to June 2018 were enrolled.They were randomly divided into 2 groups.82 patients in the control group were treated with Pivobium bromide only and 108 patients in the observation group were treated with Shugan Jieyu Capsule combined with Pivobium bromide.After 6 weeks,the treatment effects,Hamilton Depression Scale(HAMD),Hamilton Anxiety Scale(HAMA)scores and adverse reactions were compared.The recurrence and long-term adverse reactions of the two groups were observed after 6 months of follow-upResultsAfter treatment,the total effective rate(98%)and cure rate(41%)in the observation group were higher than the total effective rate(85%)and cure rate(25%)in the control group,and the difference was statistically significant(P<0.05).In the two groups,the scores of anxiety and depression were significantly lower than before(P<0.05),and the observation group was significantly better than the control group(P<0.05).For patients with ineffective treatment,reasons may be related to the time of onset,sleep disorder,depression score(P<0.05).After the treatment,the recurrence rate of the control group(12%)was significantly higher than that of the observation group(8%),which may be related to anxiety score(P<0.05).For patients without mood disorders,the total effective rate(100%)in the observation group was higher than that in the control group(86%),although the difference was not statistically significant(P=0.15),but there was a statistical trend.There was no significant difference in the adverse reactions between the observation group and the control group after treatment and during the follow-up period(P>0.05).ConclusionDiarrhea-type irritable bowel syndrome with depression or(and)anxiety is common in clinical practice.Shugan Jieyu Capsule combined with pivavironium is safe and effective in treating diarrhea-type irritable bowel syndrome,and the effect is significantly better than pivavironium only.Patients with ineffective treatment may be associated with the time of onset,sleep disorder and depression score.Patients with recurrent after treatment may be associated with anxiety levels.For patients without mood disorders,emotional drugs may bring more benefits to patients in clinical treatment.